{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T19:52:19Z","timestamp":1785786739844,"version":"3.56.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T00:00:00Z","timestamp":1620432000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1007\/s00345-021-03716-3","type":"journal-article","created":{"date-parts":[[2021,5,8]],"date-time":"2021-05-08T16:03:28Z","timestamp":1620489808000},"page":"3807-3813","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Phase I trial of intravesical Bacillus Calmette\u2013Gu\u00e9rin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette\u2013Gu\u00e9rin treatment"],"prefix":"10.1007","volume":"39","author":[{"given":"Shaheen","family":"Alanee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherjeel","family":"Sana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-Zawahry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Peabody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Pearce","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Adams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustafa","family":"Deebajah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Crabtree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristin","family":"Delfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"McVary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathy","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krishna","family":"Rao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,8]]},"reference":[{"issue":"4","key":"3716_CR1","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1016\/S0022-5347(05)67707-5","volume":"163","author":"DL Lamm","year":"2000","unstructured":"Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA et al (2000) Maintenance Bacillus Calmette-Guerin immunotherapy for recurrent TA, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study. J Urol 163(4):1124\u20131129","journal-title":"J Urol"},{"issue":"1","key":"3716_CR2","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1097\/00005392-199707000-00017","volume":"158","author":"MS Cookson","year":"1997","unstructured":"Cookson MS, Herr HW, Zhang ZF, Soloway S, Sogani PC, Fair WR (1997) The treated natural history of high risk superficial bladder cancer: 15-year outcome. J Urol 158(1):62\u201367","journal-title":"J Urol"},{"key":"3716_CR3","doi-asserted-by":"crossref","unstructured":"Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ, Sankin A, et al (2020) Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer. Urol Oncol 38(1):5 e9\u20135 e16","DOI":"10.1016\/j.urolonc.2019.05.018"},{"issue":"1","key":"3716_CR4","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3233\/BLC-159001","volume":"1","author":"SP Lerner","year":"2015","unstructured":"Lerner SP, Dinney C, Kamat A, Bivalacqua TJ, Nielsen M, O\u2019Donnell M et al (2015) Clarification of bladder cancer disease states following treatment of patients with intravesical BCG. Bladder Cancer 1(1):29\u201330","journal-title":"Bladder Cancer"},{"issue":"8","key":"3716_CR5","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I et al (2007) PD-L1 (B7\u2013H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109(8):1499\u20131505","journal-title":"Cancer"},{"key":"3716_CR6","doi-asserted-by":"crossref","unstructured":"Balar AV, Kulkarni GS, Uchio EM, Boormans J, Mourey L, Krieger LEM, et al (2019) Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-gu\u00e9rin (BCG). J Clin Oncol 37(7_suppl):350\u2013","DOI":"10.1200\/JCO.2019.37.7_suppl.350"},{"issue":"2","key":"3716_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/JU.0000000000000919","volume":"204","author":"GJ DeCastro","year":"2020","unstructured":"DeCastro GJ, Sui W, Pak JS, Lee SM, Holder D, Kates MM et al (2020) A Phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive Bacillus Calmette-Gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder. J Urol 204(2):247\u2013253","journal-title":"J Urol"},{"issue":"1","key":"3716_CR8","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","volume":"22","author":"SA Boorjian","year":"2021","unstructured":"Boorjian SA, Alemozaffar M, Konety BR, Shore ND, Gomella LG, Kamat AM et al (2021) Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol 22(1):107\u2013117","journal-title":"Lancet Oncol"},{"issue":"8","key":"3716_CR9","doi-asserted-by":"publisher","first-page":"e1338997","DOI":"10.1080\/2162402X.2017.1338997","volume":"6","author":"M Nikanjam","year":"2017","unstructured":"Nikanjam M, Patel H, Kurzrock R (2017) Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. Oncoimmunology. 6(8):e1338997","journal-title":"Oncoimmunology."},{"issue":"13","key":"3716_CR10","doi-asserted-by":"publisher","first-page":"1270","DOI":"10.1056\/NEJMc1509660","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin J, Hodi FS, Wolchok JD (2015) Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373(13):1270\u20131271","journal-title":"N Engl J Med"},{"issue":"21","key":"3716_CR11","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1056\/NEJMoa1414428","volume":"372","author":"MA Postow","year":"2015","unstructured":"Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D et al (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 372(21):2006\u20132017","journal-title":"N Engl J Med"},{"issue":"1","key":"3716_CR12","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1001\/jamaoncol.2017.2391","volume":"4","author":"AN Shoushtari","year":"2018","unstructured":"Shoushtari AN, Friedman CF, Navid-Azarbaijani P, Postow MA, Callahan MK, Momtaz P et al (2018) Measuring toxic effects and time to treatment failure for nivolumab plus ipilimumab in melanoma. JAMA Oncol 4(1):98\u2013101","journal-title":"JAMA Oncol"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03716-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-021-03716-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-021-03716-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,15]],"date-time":"2021-10-15T18:39:16Z","timestamp":1634323156000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-021-03716-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,8]]},"references-count":12,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["3716"],"URL":"https:\/\/doi.org\/10.1007\/s00345-021-03716-3","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,8]]},"assertion":[{"value":"9 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Southern Illinois University School of Medicine received research funding from MERCK and Co., Inc. for this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Approval was obtained from the Institutional Review Board of Suthern Illinois University School of Medicine and Henry Ford Health System for this study. The procedures used in this study adhere to the tenets of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Research involving human participants and\/or animals"}},{"value":"A freely given, informed consent to participate in the study was obtained from participants. No pediatric patients or patients of vulnerable populations were included in this trial.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}